Insights into the molecular mechanisms of Huangqi decoction on liver fibrosis via computational systems pharmacology approaches

被引:4
作者
Wang, Biting [1 ]
Wu, Zengrui [1 ]
Li, Weihua [1 ]
Liu, Guixia [1 ]
Tang, Yun [1 ]
机构
[1] East China Univ Sci & Technol, Sch Pharm, Lab Mol Modeling & Design, Shanghai 200237, Peoples R China
基金
中国国家自然科学基金;
关键词
Huangqi decoction; Liver fibrosis; Mechanism of action; Metabolomics; Molecular docking; Network pharmacology; PLASMINOGEN-ACTIVATOR INHIBITOR-1; HEPATIC STELLATE CELLS; BILE-DUCT LIGATION; CARBON-TETRACHLORIDE; INJURY; DISEASE; EXPRESSION; MMP-9; PROLIFERATION; INFLAMMATION;
D O I
10.1186/s13020-021-00473-8
中图分类号
R [医药、卫生];
学科分类号
10 ;
摘要
Background The traditional Chinese medicine Huangqi decoction (HQD) consists of Radix Astragali and Radix Glycyrrhizae in a ratio of 6: 1, which has been used for the treatment of liver fibrosis. In this study, we tried to elucidate its action of mechanism (MoA) via a combination of metabolomics data, network pharmacology and molecular docking methods. Methods Firstly, we collected prototype components and metabolic products after administration of HQD from a publication. With known and predicted targets, compound-target interactions were obtained. Then, the global compound-liver fibrosis target bipartite network and the HQD-liver fibrosis protein-protein interaction network were constructed, separately. KEGG pathway analysis was applied to further understand the mechanisms related to the target proteins of HQD. Additionally, molecular docking simulation was performed to determine the binding efficiency of compounds with targets. Finally, considering the concentrations of prototype compounds and metabolites of HQD, the critical compound-liver fibrosis target bipartite network was constructed. Results 68 compounds including 17 prototype components and 51 metabolic products were collected. 540 compound-target interactions were obtained between the 68 compounds and 95 targets. Combining network analysis, molecular docking and concentration of compounds, our final results demonstrated that eight compounds (three prototype compounds and five metabolites) and eight targets (CDK1, MMP9, PPARD, PPARG, PTGS2, SERPINE1, TP53, and HIF1A) might contribute to the effects of HQD on liver fibrosis. These interactions would maintain the balance of ECM, reduce liver damage, inhibit hepatocyte apoptosis, and alleviate liver inflammation through five signaling pathways including p53, PPAR, HIF-1, IL-17, and TNF signaling pathway. Conclusions This study provides a new way to understand the MoA of HQD on liver fibrosis by considering the concentrations of components and metabolites, which might be a model for investigation of MoA of other Chinese herbs.
引用
收藏
页数:17
相关论文
共 91 条
[1]  
Abdel-Latif Mohamed S, 2015, Open Microbiol J, V9, P136, DOI 10.2174/1874285801509010136
[2]   Endotoxin and Plasminogen Activator Inhibitor-1 Serum Levels Associated With Nonalcoholic Steatohepatitis in Children [J].
Alisi, Anna ;
Manco, Melania ;
Devito, Rita ;
Piemonte, Fiorella ;
Nobili, Valerio .
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION, 2010, 50 (06) :645-649
[3]   McKusick's Online Mendelian Inheritance in Man (OMIM®) [J].
Amberger, Joanna ;
Bocchini, Carol A. ;
Scott, Alan F. ;
Hamosh, Ada .
NUCLEIC ACIDS RESEARCH, 2009, 37 :D793-D796
[4]   Novel anti-angiogenic effects of formononetin in human colon cancer cells and tumor xenograft [J].
Auyeung, Kathy Ka-Wai ;
Law, Pui-Ching ;
Ko, Joshua Ka-Shun .
ONCOLOGY REPORTS, 2012, 28 (06) :2188-2194
[5]   NCBI GEO: archive for functional genomics data sets-update [J].
Barrett, Tanya ;
Wilhite, Stephen E. ;
Ledoux, Pierre ;
Evangelista, Carlos ;
Kim, Irene F. ;
Tomashevsky, Maxim ;
Marshall, Kimberly A. ;
Phillippy, Katherine H. ;
Sherman, Patti M. ;
Holko, Michelle ;
Yefanov, Andrey ;
Lee, Hyeseung ;
Zhang, Naigong ;
Robertson, Cynthia L. ;
Serova, Nadezhda ;
Davis, Sean ;
Soboleva, Alexandra .
NUCLEIC ACIDS RESEARCH, 2013, 41 (D1) :D991-D995
[6]   Liver fibrosis [J].
Bataller, R ;
Brenner, DA .
JOURNAL OF CLINICAL INVESTIGATION, 2005, 115 (02) :209-218
[7]   Genetic polymorphisms and the progression of liver fibrosis: A critical appraisal [J].
Bataller, R ;
North, KE ;
Brenner, DA .
HEPATOLOGY, 2003, 37 (03) :493-503
[8]   Critical role of plasminogen activator inhibitor-1 in cholestatic liver injury and fibrosis [J].
Bergheim, I ;
Guo, LP ;
Davis, MA ;
Duveau, I ;
Arteel, GE .
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 316 (02) :592-600
[9]   The Protein Data Bank [J].
Berman, HM ;
Battistuz, T ;
Bhat, TN ;
Bluhm, WF ;
Bourne, PE ;
Burkhardt, K ;
Iype, L ;
Jain, S ;
Fagan, P ;
Marvin, J ;
Padilla, D ;
Ravichandran, V ;
Schneider, B ;
Thanki, N ;
Weissig, H ;
Westbrook, JD ;
Zardecki, C .
ACTA CRYSTALLOGRAPHICA SECTION D-STRUCTURAL BIOLOGY, 2002, 58 :899-907
[10]   Characterization of metalloproteinases, oxidative status and inflammation levels in the different stages of fibrosis in HCV patients [J].
Capone, F. ;
Guerriero, E. ;
Sorice, A. ;
Maio, P. ;
Colonna, G. ;
Castello, G. ;
Costantini, S. .
CLINICAL BIOCHEMISTRY, 2012, 45 (7-8) :525-529